Longitude Capital Management Co., LLCFirm match from fund name (lower confidence)
Longitude Prime Fund II, L.P.
Late investment period: first sale Aug 2022, per Form D (fund age approximates vintage)
- Vintage
- 2022
- Fund size
- $49.86M to $200M (Form D)
- Stages
- Growth
- Sectors
- Biotech, Medical devices, Healthtech
- Regions
- Not stated
01 · Thesis
Longitude Capital makes venture growth investments in biotechnology, medical technology, and health solutions companies that improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. It builds balanced portfolios of clinical-stage and commercial-stage companies using venture capital, royalties, PIPEs, and equity-linked instruments.Inferred from the firm's website
02 · Initial check
$1.66M to $12.5M (estimated from fund size)
Estimated from Form D: $49.86M sold of a $200M target
03 · Who to approach
Named on this fund's Form D
- Juliet Tammenoms Bakker, Managing Member of the General Partner
- Patrick Enright, Managing Member of the General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideLongitude Capital specializes in making venture growth investments in biotechnology, medical technology, and health solutions companies that seek to improve clinical outcomes, enhance patient quality of life, and reduce the cost of care.
Longitude Capital specializes in making venture growth investments in biotechnology, medical technology, and health solutions companies that seek to improve clinical outcomes, enhance patient quality of life, and reduce the cost of care.
https://www.longitudecapital.com/
06 · Sources
Last verified: Oct 28, 2026